CBC Accelerator Network (CBCAN)
presents
Presentations of the CBC Accelerator Award
Letters of Intent (LOIs), Round 3

PART I:
Thursday, March 28, 2019
4:00 - 7:00 PM
Northwestern University
Northwestern Memorial Hospital
Feinberg Pavilion
Conference Room A
251 East Huron Street
Chicago, IL 60611

PART II:
Tuesday, April 16, 2019
4:00 - 7:00 PM
Northwestern University
Northwestern Memorial Hospital
Prentice Women’s Hospital
Room L South, 3rd Floor
250 East Superior Street
Chicago, IL 60611

The CBC gratefully acknowledges support from the Searle Funds at The Chicago Community Trust
### Time | PROGRAM |
--- | --- |
4:00 PM | PARTICIPANTS’ SELF-INTRODUCTION |
4:10 PM | INTRODUCTORY REMARKS  
**Nancy Tyrrell**, Associate Director for Translational Activities, CBC |
4:15 PM | LOI PRESENTATIONS  
**William Muller** (NU)  
*A first-in-class anti-inflammatory agent to block ischemia/reperfusion injury* |
4:35 PM | **Jeffrey Loeb** (UIC)  
*Non-invasive MR spectroscopic method to image the human epileptic brain* |
4:55 PM | **Sui Huang** (NU)  
*Chemical improvement of metarrestin, an effective anti-metastatic lead* |
5:15 PM | **C. David James** and **Jack Henkin** (NU)  
*Optimized combination chemotherapy of glioma with PEDF-derived peptide NU-335* |

### Time | NETWORKING |
--- | --- |
6:00 PM | NETWORKING RECEPTION |
7:00 PM | ADJOURN |
<table>
<thead>
<tr>
<th>Time</th>
<th>PROGRAM</th>
<th>3rd Floor, Room L South</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 PM</td>
<td>PARTICIPANTS’ SELF-INTRODUCTION</td>
<td></td>
</tr>
<tr>
<td>4:10 PM</td>
<td>INTRODUCTORY REMARKS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jim Audia, Executive Director, CBC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>and Nancy Tyrrell, Associate Director for Translational Activities, CBC</td>
<td></td>
</tr>
<tr>
<td>4:15 PM</td>
<td>LOI PRESENTATIONS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peng Ji (NU)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antithrombotic therapy using PLEK2 inhibitors</td>
<td></td>
</tr>
<tr>
<td>4:35 PM</td>
<td>Steve Ackerman and Vadim Gaponenko (UIC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel CCR3 peptide biased antagonist for therapy of eosinophilic asthma and eosinophilic esophagitis</td>
<td></td>
</tr>
<tr>
<td>4:55 PM</td>
<td>Karla Satchell (NU)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RAS processing as a strategy to reduce RAS-driven tumors</td>
<td></td>
</tr>
<tr>
<td>5:15 PM</td>
<td>Brian Kay (UIC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Best-in-class affinity reagents to Kras</td>
<td></td>
</tr>
<tr>
<td>5:35 PM</td>
<td>Gye Young Park and Michael Johnson (UIC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inhaled colony stimulating factor 1 receptor inhibitor for asthma therapy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>NETWORKING</th>
<th>3rd Floor, Harris Family Atrium</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 PM</td>
<td>NETWORKING RECEPTION</td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td>ADJOURN</td>
<td></td>
</tr>
</tbody>
</table>
About the CBC Accelerator Network (CBCAN)

The CBC Accelerator Network (CBCAN) program has created a community, bringing together industry experts, university tech transfer officers, researchers and others from the local and extended biomedical ecosystem with discoveries that may have commercial potential. The aim is to move promising discoveries into and forward in the pipeline towards commercialization, providing early commercial guidance that universities and university-based researchers need. CBCAN meetings are held quarterly or more frequently as needed.
CBC Catalyst Award

Inaugurated in 2006, the CBC Catalyst Award program has enabled Chicago scientists to pursue cutting-edge, high-risk/high-reward fundamental biomedical research with transformational potential. Collaboration between tenured or tenure-track scientists from at least two CBC universities is required in order to apply.

The CBC’s Catalyst Award program offers funding of up to $250,000 for one- or two-year new inter-institutional collaborative research projects. The fundamental structure of the Catalyst program will be maintained in Phase 2. Awards will be made based on scientific merit. Catalysts are not intended to support incremental progress, obvious next steps, or NIH-ready projects.

All applications will be reviewed for riskiness, creativity and scientific merit by the CBC Catalyst Review Board, composed of scientists from each of the CBC institutions. Applicants are encouraged to talk with past and current Catalyst Award recipients and reviewers.

Basic biomedical research projects with translational potential will be considered, although this is not the primary emphasis of the Catalyst Program. Translational proposals may be best suited for the CBC Accelerator Award program (see below). Applications requesting funding for medical devices are not eligible for the Catalyst program. Catalyst funds may not be used for correlative studies associated with ongoing clinical trials.

Key dates for the 2019 Catalyst Award program application rounds:

<table>
<thead>
<tr>
<th>Application Round</th>
<th>Proposal Online Submission</th>
<th>Expected Decision</th>
<th>Anticipated Start Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Round 27 (Spring 2019)</td>
<td>February 11-15, 2019</td>
<td>June 3, 2019</td>
<td>September 1, 2019</td>
</tr>
<tr>
<td>Round 28 (Fall 2019)</td>
<td>August 26-30, 2019</td>
<td>Dec. 18, 2019</td>
<td>March 1, 2020</td>
</tr>
</tbody>
</table>

CBC Accelerator Award Program

Established in 2018, the CBC Accelerator Award program supports translational research and provides university researchers with early commercial guidance. Accelerator Awards are to be used to support the initial, and therefore highest risk, stage of commercially-directed research focused on the development of a therapeutic or an associated biomarker or diagnostic. The program encourages interactions between academic researchers and industry/pharmaceutical experts early in the development of projects and provides advice to award recipients in setting and progressing toward commercialization milestones. Award recipients will be mentored by faculty, industry experts, tech transfer officers and CBC personnel. Accelerator awardees will provide project updates at CBCAN meetings.

Letters of Intent (LOIs) to submit translational research projects are required for initial triage by the CBC Leadership. Selected LOIs are presented at a CBCAN meeting and evaluated by the Accelerator Review Board (ARB). The finalists are invited to submit full proposals, which must discuss commercial potential, milestones and deliverables, and incorporate the ARB feedback from the CBCAN. Accelerator Awards are for $100,000 for one year.

Awarded projects that have met proposed milestones during the first year may be invited to apply for $150,000 for one additional year.
Accelerator Award Details and Eligibility:

- Applicants must be tenured or tenure-track faculty with research programs at Northwestern University, The University of Chicago, and/or University of Illinois at Chicago. Faculty with full time appointments on the clinical track at each of the institutions are also eligible to apply. Applicants must have their own designated laboratory space. Individuals who carry faculty appointments with parenthetical rank, are not eligible for tenure, and do not have their own laboratory space are not eligible to apply.

- Although collaborative proposals are encouraged there is no specific requirement for cross-institutional collaboration.

- Applicants may have created a company to pursue translation of their innovation, but there is no expectation or requirement for so doing. The CBC encourages applications prior to or without company formation.

- Multiple applications can be submitted from each institution.

- There is no expectation that Accelerator Awards will be distributed evenly among the CBC institutions.

- Proposals should show both innovation and scientific merit.

- The project should be focused on the development of a therapeutic or associated diagnostic or biomarker, built around a compelling hypothesis and focus on gathering data that advances the hypothesis and discharges key translational risks.

- Research teams should not already be funded for the same (or closely related) specific aims and/or milestones.

- Research projects described in Accelerator applications cannot be under review at other funding institutions/agencies to support the same (or closely related) specific aims and/or milestones.

- A PI may participate in only one application per round.

- Ongoing and active participation in the CBCAN program is a requirement for Accelerator Award recipients.

Key dates for the 2019 Accelerator Award program application rounds:

<table>
<thead>
<tr>
<th>Application Round</th>
<th>LOI Online Submission</th>
<th>LOI Presentations at CBCAN</th>
<th>Full Proposal Online Submission</th>
<th>Funding Decisions Expected</th>
<th>Anticipated Start Date</th>
</tr>
</thead>
</table>
Entrepreneurial Fellows

The CBC Entrepreneurial Fellows (EF) Award program identifies and supports the professional development of academic researchers who are keen to acquire the skills and experiences needed to move translational projects from a university lab toward commercialization and potentially into a Chicago-based biotech start-up. The program exposes Fellows to a breadth of real-world experiences with the full span of their home institution and across the CBC community. Fellows will receive guidance from a wide range of mentors, including university faculty, staff and tech transfer, industry experts and other representatives of the biomedical community.

Applications are now being accepted for CBC-Northwestern Entrepreneurial Fellows. Additional CBC Entrepreneurial Fellowships will be introduced at UIC and UChicago later in 2019. Applications for the initial class of Entrepreneurial Fellows will be accepted on a rolling basis until May 1, 2019 or until the positions are filled.

Program Details and Eligibility:

- The CBC-NU Entrepreneurial Fellow will be a recent PhD or MD/PhD recipient or will have recently completed an initial postdoc in the biomedical sciences with a strong interest and passion for driving innovative and transformational biomedical research from the university toward clinical and ultimately commercial applications.

- Working closely with the CBC Executive Director, Scientific Directors and staff, partners in NU's Innovation and New Venture Office (INVO) and NU faculty from both the Evanston and Chicago campuses, the Fellow will have an active and central role in the development, refinement and implementation of CBC-funded awards focused on translational research, including CBC Accelerator Award and CBC Catalyst Award projects.

- The Fellow will also support Lakeside Discovery (LD), a collaboration between NU and Deerfield Management, to accelerate translation of university-based biomedical discoveries that have therapeutic and commercial potential.

- The Fellow will work closely with the initiating laboratory, under the guidance of the LD Alliance Director, to develop a robust work plan which advances the biology toward pre-clinical (and ultimately clinical) proof-of-concept while assessing and subsequently addressing drug discovery/development risk.

- During this process, the Fellow will be exposed to all aspects of drug discovery and early development, including development of robust project plans, time-lines, budgets, competitive landscapes and clinical strategies.

- The Fellow will also play an important role within the CBC and greater Chicago biomedical community, participating actively in CBC-sponsored events such as CBCAN, CBC scientific symposia and workshops.

The EF Award program offers:

- Highly competitive salary with fringe benefits.

- Funds are available for travel associated with program responsibilities and professional development.

- Office located in INVO and shared with other CBC NU EFs.

- Appointments are for 12 months but are renewable for an additional 12 months by mutual agreement.
The mission of the Chicago Biomedical Consortium (CBC) is to stimulate collaboration among scientists at Northwestern University, The University of Chicago, the University of Illinois at Chicago and others to accelerate discovery that will transform biomedical research and improve the health of humankind. The CBC will:

- Stimulate research and education that bridge institutional boundaries,
- Enable collaborative and interdisciplinary research that is beyond the range of a single institution,
- Mentor and develop a strong cadre of biomedical leaders, researchers, and entrepreneurs in Chicago,
- Enhance and promote the development of the biomedical ecosystem in Chicago,
- Facilitate development of therapeutics that will, over the long term, improve the health of citizens of Chicago and beyond.

**CBC Leadership**

**Jim Audia, PhD**, Executive Director, Northwestern University  
T: 847-467-6745 | E: jeaudia1@northwestern.edu  

**Luisa DiPietro, DDS, PhD**, Scientific Director, University of Illinois at Chicago  
T: 312-355-0432 | E: Ldipiet@uic.edu  

**Lucy Godley, MD, PhD**, Scientific Director, The University of Chicago  
T: 773-702-4140 | E: lgodley@medicine.bsd.uchicago.edu  

**Richard Morimoto, PhD**, Scientific Director, Northwestern University  
T: 847-491-3340 | E: r-morimoto@northwestern.edu  

**CBC Staff**

**Kimberly Corn**, Associate Director, Business Operations and Finance, Northwestern University  
T: 847-467-0357 | E: k-corn@northwestern.edu  

**Jola Glotzer, MD**, Communications Director, The University of Chicago  
T: 773-834-5132 | E: jolaglotzer@uchicago.edu  

**Corinna Kitcharoen, MBA**, Program Coordinator, University of Illinois at Chicago  
T: 312-355-3683 | E: ckitch1@uic.edu  

**Molly Reese, MA**, Executive Assistant to Jim Audia, Northwestern University  
T: 847-467-4983 | E: molly.reese@northwestern.edu  

**Karen Snapp, DDS, PhD**, Senior Associate Director, Northwestern University  
T: 847-467-0633 | E: ksnapp@northwestern.edu  

**Nancy Tyrrell**, Associate Director for Translational Activities, Northwestern University  
T: 847-467-1094 | E: nancy.tyrrell@northwestern.edu  

www.chicagobiomedicalconsortium.org